2月13日 - ** 生命科学公司Bio-Rad LaboratoriesBIO.N股价盘前大跌15.3%，至247.75美元。
** 该公司周三公布的第四季度调整后 每股利润为2.51美元，低于LSEG汇编的分析师平均预期的2.70美元。
** 然而，6.932亿美元的营收超过了分析师平均预期的6.8876亿美元。
** 由于学术研究和生物技术资金的限制，生命科学部门的季度销售额同比下降了2.6%，为2.679亿美元。
** 截至上一交易日收盘，股价累计下跌 3.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.